The emergence of amivantamab represents a exciting development for people battling cancers exhibiting c-MET overexpression. This novel therapeutic, a selective inhibitor of multiple MET kinase plus human epidermal growth factor receptor 2 (HER2), revealed preliminary results in clinical studies,